Assenagon Asset Management
BLCM

Assenagon Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Assenagon Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,691
Closed -$225K – 1211
2019
Q1 		$225K Buy
+6,691
New +$224K ﹤0.01% 886

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management's BLCM Position: Q2 2019 in Review

Assenagon Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 6,691 shares — an estimated $225K sold.

Assenagon Asset Management first reported a position in BLCM in Q1 2019 and held it in 1 quarter. The position peaked at $225K in Q1 2019. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

  • Assenagon Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 6,691 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $225K.
  • Assenagon Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • Assenagon Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $225K in Q1 2019.
  • 79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Assenagon Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.